An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Good day, and thank you for standing by. Welcome to the Nanobiotix Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded ...
An update from Nanobiotix ( (NBTX)) is now available. Nanobiotix announced on March 26, 2026, that it would release its fourth-quarter and full-year 2025 financial and operational results after the ...
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy ...
The average one-year price target for Nanobiotix S.A. - Depositary Receipt (NasdaqGS:NBTX) has been revised to $25.86 / share. This is an increase of 12.06% from the prior estimate of $23.08 dated ...
Hosted on MSN
Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. 10 stocks we like better than ...
Nanobiotix (NASDAQ: NBTX) is a French biotechnology stock, and one that has soared 660% in 2025 as of Nov. 18. That's enough to draw investor attention, and to have many wondering if such torrid ...
Nanobiotix is a small French biotechnology company. It has secured financing from Johnson & Johnson and elsewhere. It's not a no-brainer investment, but it might do well. Nanobiotix (NASDAQ: NBTX) is ...
PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Nanobiotix today and set a price target of $24.00. The company’s shares closed yesterday at $18.89. Take advantage of TipRanks ...
Investing.com -- Nanobiotix (NASDAQ:NBTX) stock surged 10.9% Tuesday following the presentation of encouraging clinical trial data for its cancer treatment JNJ-1900 (NBTXR3) at the American Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results